SCHEMBL3582487

SCHEMBL3582487

CCOC(=O)c1c(C)nn(C)c1NC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 4/20 0.46
ALDH1A1 P00352 5/20 0.44
LMNA P02545 4/20 0.44
MAPK1 P28482 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
PKM P14618 1/20 0.44
HTT P42858 1/20 0.44
MCOLN3 Q8TDD5 1/20 0.44
KDM4E B2RXH2 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
KMT2A Q03164 1/20 0.42
PDE4B Q07343 1/20 0.42
USP2 O75604 1/20 0.41
GLA P06280 1/20 0.40
MAPT P10636 2/20 0.40
P2RY12 Q9H244 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA7 P43166 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26290561 0.84 KMT2A (0.41) PDE4DALDH1A1LMNAPKMHTT
SCHEMBL10361155 0.83 PDE4D (0.46) PDE4DALDH1A1LMNAMAPK1NPSR1
SCHEMBL8784515 0.81 PDE4D (0.56) PDE4DALDH1A1MAPK1NPSR1KDM4E
SCHEMBL26104148 0.79 PDE4D (0.48) PDE4DALDH1A1LMNAMAPK1NPSR1
SCHEMBL21974579 0.78 PDE4D (0.47) PDE4DALDH1A1LMNAMAPK1NPSR1
SCHEMBL2963689 0.78 L3MBTL1 (0.53) PDE4DALDH1A1LMNAMAPK1KDM4E
SCHEMBL10577895 0.78 MAPK1 (0.56) PDE4DALDH1A1LMNAMAPK1PKM
SCHEMBL3575606 0.77 KDM4E (0.46) ALDH1A1LMNAKDM4EL3MBTL1KMT2A
SCHEMBL23123432 0.77 KMT2A (0.46) PDE4DALDH1A1LMNAMAPK1NPSR1
SCHEMBL10362229 0.77 PDE4D (0.46) PDE4DALDH1A1LMNAMAPK1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984340-B1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2012-06-27 EP disclosed
US-7678818-B2 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. (US) 2010-03-16 US disclosed
EP-1984340-A1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-10-29 EP disclosed
US-20070219261-A1 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. 2007-09-20 US disclosed
WO-2007090752-A1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219261-A1 Anthranilamide and 2-amino-heteroarene-carboxamide compounds AADAT, AAAS, AADAC PDE4D 3019/4885ALDH1A1 1414/4885LMNA 1337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.